Placebo to Povorcitinib
Sponsors
Incyte Corp.
Conditions
Prurigo NodularisVitiligo
Phase 3
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
Active, not recruitingCTIS2023-506011-18-00
Start: 2024-04-17Target: 281Updated: 2025-09-22
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
Active, not recruitingCTIS2023-505782-86-00
Start: 2024-04-23Target: 203Updated: 2025-12-22
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis
RecruitingCTIS2024-511879-16-00
Start: 2024-12-12Target: 162Updated: 2026-01-21
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis
RecruitingCTIS2024-511881-35-00
Start: 2024-12-17Target: 170Updated: 2026-01-27